Dry eye
Conditions
Interventions
Cyclosporine eye drops group :Thirty patients (eyes) received postoperative treatment with cyclosporine eye drops four times a day for a total of one month, tobramycin dexamethasone eye drops, gatiflo
Perfluorohexaneoctane eye drops group:Thirty patients (eyes) received postoperative treatment with perfluorohexaneoctane eye drops four times a day for a total of one month, tobramycin dexamethasone e
Diquat Sodium Eye Drops Group:Thirty patients (eyes) received postoperative treatment with diquat sodium eye drops four times a day for one month, tobramycin dexamethasone eye drops, gatifloxacin eye
Control group :Postoperative use of only tobramycin dexamethasone eye drops, gatifloxacin eye drops,recombinant bovine basic fibroblast growth factor ophthalmic gelthree times a day for 2 weeks, and P
Sponsors
The First People's Hospital of Zigong City
Eligibility
Sex/Gender
All
Age
50 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.50~75 years old meet the diagnostic criteria for type 2 diabetes, and meet the criteria for cataract surgery. The grading of lens nucleus (Emery method) is ? to ?, which is suitable for phacoemulsification. The diagnosis of diabetes is mainly based on the clinical course, symptoms and corresponding auxiliary examination results. 2.Capable and willing to accept research visits at all time periods and sign informed consent forms. All cataract patients were treated with tobramycin dexamethasone eye drops, gatifloxacin eye drops three times a day for 2 weeks, and Praprofen eye drops three times a day for 1 month after surgery.
Exclusion criteria
Exclusion criteria: 1.Systemic connective tissue diseases and autoimmune diseases (such as systemic lupus erythematosus, gout, rheumatoid arthritis, and other rheumatic and immunological diseases); 2.Diseases that have a significant impact on tear secretion and dry eye risk (such as Sjogren's syndrome, Steve Johnson syndrome, and thyroid related systemic diseases); 3.Known pathological factors that affect the surface of the eye (such as eyelid retraction, eyelid injury, incomplete eyelid closure, dacryocystitis, and pterygium); 4.Active inflammation, allergic ocular surface diseases, and history of contact lens use in the eye within 3 months. 5.Coexistence of eye diseases (such as concomitant eye trauma, uveitis, high intraocular pressure or glaucoma, keratoconjunctivitis, etc.); 6.History of eye surgery and eye laser surgery within 6 months; 7.Use of local eye drops such as steroids, artificial tears, nonsteroidal anti-inflammatory drugs (NSAIDs), and anti glaucoma drugs within 3 months before surgery; 8.Use of large ultrasound energy for nucleus hardness grade IV or above (Emery method) 9.Use of other sensitive drugs during the perioperative period, participation in other clinical trials during follow-up, or non cooperation or non-compliance in diagnostic tests during follow-up. If patients experience serious complications during or after surgery, such as corneal epithelial or endothelial damage, retrobulbar or intrabulbar bleeding, or postoperative high intraocular pressure, uveitis, persistent corneal edema, bullous keratopathy, endophthalmitis, etc., they will be withdrawn from the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Tear fern like transformation; Thickness of tear film lipid layer;Break-up time,BUT;Tear osmotic pressure;Higher order aberrations;OSDI;Tear mucin;Irregular astigmatism of cornea;Tears river height; | — |
Secondary
| Measure | Time frame |
|---|---|
| Extent of ocular surface epithelial cell damage;Corneal optical density; | — |
Countries
China
Contacts
Public ContactShuangle Li
The First People's Hospital of Zigong City
Outcome results
None listed